ATE271130T1 - Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können - Google Patents

Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können

Info

Publication number
ATE271130T1
ATE271130T1 AT98906268T AT98906268T ATE271130T1 AT E271130 T1 ATE271130 T1 AT E271130T1 AT 98906268 T AT98906268 T AT 98906268T AT 98906268 T AT98906268 T AT 98906268T AT E271130 T1 ATE271130 T1 AT E271130T1
Authority
AT
Austria
Prior art keywords
substrates
disclosed
modified
methods
engineered
Prior art date
Application number
AT98906268T
Other languages
English (en)
Inventor
Kevan M Shokat
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Application granted granted Critical
Publication of ATE271130T1 publication Critical patent/ATE271130T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
AT98906268T 1997-02-07 1998-02-09 Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können ATE271130T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79752297A 1997-02-07 1997-02-07
US4672797P 1997-05-16 1997-05-16
PCT/US1998/002522 WO1998035048A2 (en) 1997-02-07 1998-02-09 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates

Publications (1)

Publication Number Publication Date
ATE271130T1 true ATE271130T1 (de) 2004-07-15

Family

ID=26724237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906268T ATE271130T1 (de) 1997-02-07 1998-02-09 Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können

Country Status (8)

Country Link
US (5) US6390821B1 (de)
EP (1) EP1017823B1 (de)
JP (2) JP3784076B2 (de)
AT (1) ATE271130T1 (de)
AU (1) AU755062B2 (de)
CA (1) CA2279846C (de)
DE (1) DE69825066T2 (de)
WO (1) WO1998035048A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017823B1 (de) * 1997-02-07 2004-07-14 Princeton University Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
US6162613A (en) * 1998-02-18 2000-12-19 Vertex Pharmaceuticals, Inc. Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
US7383135B1 (en) 1998-05-04 2008-06-03 Vertex Pharmaceuticals Incorporated Methods of designing inhibitors for JNK kinases
US6610483B1 (en) * 1999-07-23 2003-08-26 Princeton University Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof
DE10024174A1 (de) * 2000-05-17 2001-11-29 Gsf Forschungszentrum Umwelt Verfahren zum Selektieren von Inhibitoren für Enzyme
AU2001286931A1 (en) * 2000-08-30 2002-03-13 The Salk Institute For Biological Studies Methods and compositions for determining isomerase enzymatic activity
WO2002057418A2 (en) * 2000-12-15 2002-07-25 The Salk Institute For Biological Studies Methods of producing polyketide synthase mutants and compositions and uses thereof
EP2295550A3 (de) 2001-04-30 2011-12-14 Vertex Pharmaceuticals Incorporated Kristallstrukturen von GSK-3-beta-Protein und -Proteinkomplexen und deren Verwendung
US20060263800A1 (en) * 2001-11-01 2006-11-23 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
WO2003105723A2 (en) * 2002-06-14 2003-12-24 The Salk Institute For Biological Studies Mutant plant caffeic acid/5-hydroxyferulic acid 3/5-0-methyltransferases (comt), methods for preparation and use thereof
WO2004024082A2 (en) * 2002-09-13 2004-03-25 Irm, Llc Highly specific modulators of gtpases for target validation
TW200418498A (en) * 2002-09-30 2004-10-01 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US7452893B2 (en) 2003-08-15 2008-11-18 Merck & Co., Inc. 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists
EP2039349A1 (de) * 2004-10-19 2009-03-25 KRKA, tovarna zdravil, d.d., Novo mesto Feste pharmazeutische Zusammensetzung mit Donepezilhydrochlorid
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US20090215080A1 (en) * 2005-10-13 2009-08-27 Activesite Pharmaceuticals Methods for identification of inhibitors of enzyme activity
KR20150038395A (ko) * 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US7890417B2 (en) * 2007-01-31 2011-02-15 Bids Trading, L.P. Electronic block trading system and method of operation
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
WO2009102867A1 (en) * 2008-02-12 2009-08-20 Bids Trading, L.P. Real-time portfolio balancing and/or optimization system and method
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (de) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Festen formen von isochinolinonen
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2976086B1 (de) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Kombination aus katalytischen mtorc 1/2-inhibitoren und selektiven inhibitoren der aurora-a-kinase
US10769725B1 (en) 2013-06-05 2020-09-08 Bids Trading, L.P. System and methods for optimizing the effectiveness of interaction between participants in an electronic trading environment
EP3964507A1 (de) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und verwendungen davon
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (de) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Kombinationstherapie
EP3801069A4 (de) 2018-06-01 2022-03-16 Cornell University Kombinationstherapie für eine pi3k-assoziierte erkrankung oder störung
WO2021133915A1 (en) * 2019-12-23 2021-07-01 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
US20230417751A1 (en) * 2021-05-13 2023-12-28 Texas Tech University System Analysis of protein kinases in live cells
WO2023133354A2 (en) 2022-01-10 2023-07-13 Southern Research Institute Development of potential antidotes for arsenicals

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
CA2054602C (en) 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5914393A (en) * 1995-12-05 1999-06-22 Incyte Pharmaceuticals, Inc. Human Jak2 kinase
CA2266519C (en) 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
EP1017823B1 (de) 1997-02-07 2004-07-14 Princeton University Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6162613A (en) 1998-02-18 2000-12-19 Vertex Pharmaceuticals, Inc. Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
US5965352A (en) 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
US6610483B1 (en) 1999-07-23 2003-08-26 Princeton University Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof

Also Published As

Publication number Publication date
DE69825066T2 (de) 2005-08-25
JP2004248675A (ja) 2004-09-09
US6521417B1 (en) 2003-02-18
WO1998035048A3 (en) 1999-01-07
US7049116B2 (en) 2006-05-23
CA2279846C (en) 2008-06-03
JP3784076B2 (ja) 2006-06-07
EP1017823B1 (de) 2004-07-14
AU755062B2 (en) 2002-12-05
CA2279846A1 (en) 1998-08-13
MX9907317A (es) 2002-09-02
WO1998035048A2 (en) 1998-08-13
AU6153598A (en) 1998-08-26
JP2002503953A (ja) 2002-02-05
US20020146797A1 (en) 2002-10-10
DE69825066D1 (de) 2004-08-19
US20020016976A1 (en) 2002-02-07
US7026461B1 (en) 2006-04-11
US6390821B1 (en) 2002-05-21
EP1017823A2 (de) 2000-07-12

Similar Documents

Publication Publication Date Title
DE69825066D1 (de) Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
DE69731226D1 (de) Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten
ATE316147T1 (de) Enzymsensor
ATE248170T1 (de) Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
DE69739898D1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
ATE419392T1 (de) Verfahren zum nachweis von alkyliertem cytosin in dna
DE60009575D1 (de) Nachweis von bakterien und bakteriophagen mit immobilisierten enzymsubstraten
AU1929199A (en) Methods for the recovery and measurement of troponin complexes
MXPA03007786A (es) Amplificacion de sonda circular usando iniciadores de transferencia de energia.
DK1454992T3 (da) Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf
ATE445158T1 (de) Toxizitätstypisierung unter verwendung von leberstammzellen
AU5604900A (en) Phosphorylation assays
WO2002047535A3 (en) High throughput assay to detect inhibitors of the map kinase pathway
EP1395275A4 (de) Beta-secretase-substrate und ihre verwendung
WO2001007088A3 (en) Methods for treating therapy-resistant tumors
ATE238551T1 (de) Homogene nachweisverfahren zur bestimmung der phosphorylierungsaktivitäten von biologischem material
ATE288922T1 (de) Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
GB9710154D0 (en) Detection of retroviruses
ATE440964T1 (de) Verfahren zur detektion von polynukleotidkinase und deren verwendung als markierung
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
FR2875242B1 (fr) Nouveaux substrats enzymatiques derives de phenoxazinone et leur utilisation comme revelateur dans la detection de microorganismes a activite peptidase
BG108513A (en) METHOD FOR SCINTILLATION IDENTIFICATION OF AMINOGLYCOZIDE-BINDING MOLECULES (ABMs)
AU2002220797A1 (en) Method for identifying listeria monocytogenes and culture medium
FR2779430B1 (fr) Dithio-bis-nitrobenzenes substitues et leurs applications
WO2002010439A3 (en) Macromolecular enzyme substrates

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties